{
  "id": 14220644,
  "title": "Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds",
  "url": "https://urgent.news/2026/10/13/triple-action-drug-retatrutide-delivers-major-weight-loss-for-people",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T14:20:37.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-triple-action-drug-retatrutide-major.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}